Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]
News [11457]
Articles [47]
Editorials [10]
Conferences [200]
elearning [4]
Clinical trial of adjuvant therapy combination shows improved recurrence-free survival in liver cancer patients at high-risk of recurrence
Clinical trial of adjuvant therapy combination shows improved recurrence-free survival in liver cancer patients at...
US National Cancer Institute Center for Global Health survey on clinical trials in low-and middle-income countries
US National Cancer Institute Center for Global Health survey on clinical trials in low-and middle-income countries
ESMO 2023: Amivantamab plus lazertinib resulted in 30 percent reduction in risk of disease progression or death compared to osimertinib in patients with EGFR-mutated NSCLC
ESMO 2023: Amivantamab plus lazertinib resulted in 30 percent reduction in risk of disease progression or death...
ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive mCRPC in the pre-taxane setting
ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant...
ESMO 2023: Cabozantinib dramatically improved progression-free survival in advanced neuroendocrine tumours
ESMO 2023: Cabozantinib dramatically improved progression-free survival in advanced neuroendocrine tumours
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with...
ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus
ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus
ESMO 2023: Dual-action drug produces positive results in patients with advanced neuroendocrine tumours, trial finds
ESMO 2023: Dual-action drug produces positive results in patients with advanced neuroendocrine tumours, trial finds
ESMO 2023: Advances in gynaecological cancer research could change the treatment landscape
ESMO 2023: Advances in gynaecological cancer research could change the treatment landscape
ESMO 2023: Lung cancer treatment research enters a new era
ESMO 2023: Lung cancer treatment research enters a new era

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation